Browse the evidence

Metabolic and bariatric surgery (MBS) is associated with a significantly lower risk of major adverse cardiovascular events (MACE) and all-cause mortality compared to treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) in patients with type-2 diabetes and severe obesity.

For patients with type-2 diabetes and severe obesity, metabolic surgery appears to offer better protection against major heart events and death than treatment with GLP-1 medications alone. While surgery carries a small risk of complications, the long-term cardiovascular benefits outweigh these risks compared to pharmacological management. Patients should discuss these specific cardiovascular outcomes with their healthcare providers when choosing between surgical and medical management.

Gut microbiota composition and function are altered in type 2 diabetes, characterized by reduced diversity and decreased abundance of butyrate-producing bacteria, which is associated with insulin resistance and increased diabetes risk.

People with type 2 diabetes often have less diverse gut bacteria and fewer bacteria that produce butyrate. This is a consistent finding, but it doesn't mean there's a single 'bad bacteria' to target. Focus on dietary patterns that support overall microbial diversity.

If initial double combination therapy fails to control HbA1c, a triple combination of metformin, SGLT-2 inhibitor, and GLP-1 receptor agonist is recommended as the best treatment to reduce cardiovascular events and mortality.

If your first two medications don't control your blood sugar, add a third: a combination of metformin, an SGLT-2 inhibitor, and a GLP-1 receptor agonist. This is the most effective way to protect your heart and kidneys based on current real-world evidence.

Insulin should be the first-line treatment if insulin deficiency is the predominant factor at the onset of type 2 diabetes, followed by cardio-renal protective medications.

If your body isn't making enough insulin, start with insulin therapy first. After stabilizing your blood sugar with insulin, add medications that protect your heart and kidneys (SGLT-2 inhibitors or GLP-1 receptor agonists).

Resmetirom, a selective thyroid hormone receptor beta (THRβ) agonist, significantly reduces hepatic steatosis, liver fibrosis, and serum lipid levels (LDL, TG, ApoB) in patients with MASLD, particularly those with fibrosis.

For patients with fatty liver disease who have developed early scarring (fibrosis), Resmetirom is a new medication that targets the liver specifically to burn fat and reduce scarring. It also lowers bad cholesterol (LDL) and triglycerides. Clinical trials show it significantly improves liver health markers.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and dual/triple incretin agonists (e.g., tirzepatide, retatrutide) significantly reduce hepatic steatosis and liver enzymes in patients with MASLD, primarily through indirect mechanisms of weight loss and improved insulin resistance, though they may not consistently resolve fibrosis.

If you have MASLD, especially with diabetes or obesity, GLP-1 based therapies (like semaglutide or tirzepatide) are highly effective at reducing liver fat and inflammation. However, do not expect them to reverse advanced scarring (fibrosis) on their own. The benefit comes largely from the weight loss and metabolic control they provide, so they work best when combined with lifestyle changes.

Ketogenic diets produce superior short-term glycemic control (HbA1c reduction) compared to low-carbohydrate diets, but are not superior to other dietary patterns for long-term weight loss or metabolic outcomes.

If you have Type 2 Diabetes, a strict ketogenic diet (20-50g carbs/day) can lower your HbA1c faster than standard low-carb diets in the short term. However, do not expect it to help you lose more weight in the long run compared to other healthy diets. It is a tool for glycemic control, not a magic bullet for weight loss.

Targeting specific inflammatory pathways (e.g., IL-1, TNFα, IL-6) with pharmacological antagonists can improve insulin sensitivity and glycemic control in patients with obesity and related inflammatory conditions.

In clinical settings, reducing inflammation through targeted medications can help manage blood sugar and insulin resistance in obese patients, especially those with co-existing inflammatory diseases. This supports the broader goal of reducing metabolic risk.

Tirzepatide improves cardiovascular risk factors, including lipid profiles and blood pressure, without increasing cardiovascular event risk in T2DM patients.

Beyond weight loss, Tirzepatide improves heart health markers by lowering bad fats (triglycerides, LDL) and raising good fats (HDL), while also lowering blood pressure. It does not appear to increase heart attack or stroke risk in T2DM patients.

Adaptive thermogenesis is associated with significant hormonal changes, specifically decreased leptin and T3, and reduced resting heart rate.

Low leptin and T3 levels are expected during a cut and contribute to metabolic slowdown. This is a normal hormonal response to energy deficit.

GLP-1RAs reduce food intake and body weight by activating POMC neurons and inhibiting NPY/AgRP neurons in the arcuate nucleus (ARC) of the hypothalamus.

GLP-1 medications also work in the brain's 'hunger center' (arcuate nucleus) by boosting 'stop eating' signals (POMC) and reducing 'start eating' signals (NPY/AgRP). This dual action helps reduce overall food intake and body weight.

Discontinuation of anti-obesity medications (AOMs) leads to significant weight regain starting at 8 weeks post-treatment, with the trajectory stabilizing by 26 weeks.

If you stop taking anti-obesity medication, expect to regain weight starting around 2 months later. This is a biological response to the loss of the drug's appetite-suppressing effects, not a lack of willpower. Long-term management likely requires ongoing treatment or intensive lifestyle support to counteract this regain.

GLP-1 analogs and SGLT-2 inhibitors are promising therapeutic modalities for the obese-diabetic phenotype of HFpEF, with GLP-1 analogs showing significant reduction in epicardial adipose tissue (EAT) and body weight.

Newer diabetes drugs (GLP-1s and SGLT-2 inhibitors) are highly effective for obese HFpEF patients. They help lose weight, reduce heart fat (EAT), and improve heart function. GLP-1s like semaglutide can lead to substantial weight loss (up to 10% or more).

Triple agonists (GLP-1/GIP/Glucagon) like retatrutide achieve even greater weight loss (>24%) than dual agonists, likely due to the addition of glucagon receptor agonism which increases energy expenditure.

Triple-agonist injections like retatrutide (12 mg/week) are showing even higher weight loss rates (~24%) than current dual agonists in early trials. This is due to the addition of glucagon stimulation, which boosts energy expenditure. These are still in development and not yet widely approved for obesity.

Bariatric surgery yields significantly higher rates of complete and prolonged diabetes remission compared to usual care (lifestyle and medication management).

For patients with Type 2 Diabetes, bariatric surgery is a more effective intervention for achieving remission than lifestyle changes and medications alone. While surgery carries risks and potential for relapse, the data shows it significantly outperforms standard care in both complete and prolonged remission rates. Patients should discuss their eligibility and specific surgical options (like RYGB or Sleeve Gastrectomy) with their healthcare provider, weighing the higher remission probability against surgical risks.

Bariatric surgery patients often have higher baseline HbA1c and require more insulin, yet still achieve higher remission rates than usual care patients.

Even if your diabetes is severe (high HbA1c) or you require insulin, bariatric surgery may still offer a chance for remission, potentially more so than lifestyle changes alone. Do not rule out surgery solely based on the severity of your diabetes or current medication use.

GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) and slow chronic kidney disease progression in Type 2 Diabetes, but evidence for improving heart failure outcomes is mixed or insufficient.

If you have Type 2 Diabetes and high heart risk or kidney issues, GLP-1 agonists (like Ozempic, Trulicity, or Victoza) are highly recommended to prevent heart attacks and protect kidneys. However, they are not currently proven to treat existing heart failure. If you struggle with injections, ask about oral semaglutide.

GLP-1 receptor agonists reduce the risk of heart failure hospitalization, with the most significant relative risk reduction observed in patients with heart failure with preserved ejection fraction (HFpEF) who have obesity.

If you have heart failure with preserved ejection fraction (HFpEF) and are overweight or obese, GLP-1 medications like semaglutide or efpeglenatide may significantly reduce your risk of being hospitalized for heart failure. These drugs work by improving blood sugar, reducing weight, and lowering inflammation. While not yet a standard treatment for all heart failure, they are a promising option, especially for those with obesity.

Bile acids, particularly lithocholic acid and hyocholic acid, improve glucose tolerance by activating the GPCR GPBAR1 (TGR5) on enteroendocrine cells, leading to increased GLP-1 secretion and insulin release.

Bile acids play a crucial role in glucose regulation by activating the GPBAR1 receptor, which stimulates the release of GLP-1 and insulin. This effect is particularly pronounced after meals containing fats and cholesterol, as bile acid levels rise. Post-bariatric surgery patients often experience improved glucose tolerance due to increased circulating bile acids. Maintaining a healthy gut microbiome may also influence bile acid composition and effectiveness.

Unsaturated fatty acids, particularly omega-3 PUFAs like linoleic, oleic, and docosahexaenoic acid, stimulate insulin and glucagon secretion via activation of FFAR1 and FFAR4, improving glucose tolerance.

Incorporate unsaturated fatty acids, especially omega-3 PUFAs found in fish, nuts, and seeds, into your diet. These fatty acids activate FFAR1 and FFAR4 receptors, which can stimulate the release of insulin and glucagon, helping to regulate blood sugar levels. This is particularly beneficial for individuals with insulin resistance or type 2 diabetes.

Semaglutide improves NASH resolution in patients with stage 1-3 fibrosis but does not improve fibrosis or NASH resolution in patients with NASH-related cirrhosis.

Semaglutide can help resolve NASH in patients with early to moderate fibrosis, but it is not effective for reversing scarring in advanced cirrhosis, even if it helps with weight and metabolic markers.

Semaglutide achieves the highest response rate for NASH resolution without worsening fibrosis in clinical trials, but does not reverse fibrosis despite significant weight loss.

Semaglutide is currently the most effective drug for resolving NASH without worsening fibrosis, but it does not reverse existing fibrosis. It should be considered for patients who do not achieve goals with lifestyle changes alone, under medical supervision.

Tirzepatide treatment (5-15 mg once weekly) reduces albuminuria (UACR) without causing adverse changes in estimated glomerular filtration rate (eGFR) in individuals with overweight or obesity, with or without type 2 diabetes.

If you have overweight or obesity, with or without type 2 diabetes, tirzepatide (a weekly injection) has been shown to improve kidney markers (specifically reducing albuminuria) without negatively impacting kidney filtration function. This benefit was observed across different doses (5-15 mg) over 72 weeks, alongside lifestyle changes. This suggests it may be a kidney-protective option for this population, particularly those with existing elevated albuminuria.

Discontinuation of GLP-1 RA therapy is associated with significant weight regain, loss of cardiorenal protection, and an increased risk of Major Adverse Cardiovascular Events (MACE).

If you stop taking your GLP-1 medication (like Ozempic or Wegovy), you are likely to regain much of the weight you lost. More importantly, studies show that stopping these drugs increases your risk of heart attacks, strokes, and other cardiovascular events. If you are considering stopping due to side effects, talk to your doctor about adjusting the dose or switching medications rather than stopping abruptly, to protect your heart and maintain your weight loss.